Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma

Documenti analoghi

• A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients
  di: Jelena Jelicic, et al.
  Pubblicazione: (2024)
• 302 | PREDICTING OUTCOMES IN DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS ELIGIBLE FOR FRONT‐LINE TRIALS USING HARKINS' ENHANCED ELIGIBILITY CRITERIA
  di: J. Jeličić, et al.
  Pubblicazione: (2025)
• The Prevalence of Diffuse Large B‐Cell Lymphoma Varies Substantially by Methods Applied: Results From a Population‐Based Study
  di: Mikkel Runason Simonsen, et al.
  Pubblicazione: (2024)
• Population‐based survival after mantle cell lymphoma in Norway and Denmark: Limited impact of earlier BTKi access
  di: Mikkel Runason Simonsen, et al.
  Pubblicazione: (2026)
• Effectiveness of R‐CHOP versus R‐CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study
  di: Rasmus Rask Kragh Jørgensen, et al.
  Pubblicazione: (2024)